Collaboration Between Philips and Polarean Allows Routine MRI Access to High-Res Imaging of Lung Ventilation
The combination of Philips’ MR 7700 multi-nuclei scanner with the FDA-approved Xenoview hyperpolarized Xenon magnetic resonance imaging (MRI) contrast agent may facilitate earlier diagnosis and intervention for patients with obstructive lung diseases.
High-resolution imaging of lung ventilation may be more accessible through routine magnetic resonance imaging (MRI) applications thanks due to a new collaboration between Philips and Polarean announced at the 2023 International Society for Magnetic Resonance in Medicine Annual Meeting and Exhibition (ISMRM) in Toronto, Canada.
Combining the fully integrated multi-nuclei imaging of Philips’ 3T MR 7700 system with Xenoview™ (Polarean), a hyperpolarized Xenon-based MRI contrast agent, provides greater detail in lung imaging and accuracy in measuring lung ventilation, according to Philips. Xenoview was approved by the Food and Drug Administration (FDA) in January for use with MRI in the assessment of lung ventilation for adults and children 12 years of age and older.
Philips says the combination of Philips MR 7700 and Xenoview could have a significant impact in facilitating early diagnosis in patients with pulmonary disease.
“This technology is groundbreaking and is already starting to make a difference to patients and providers, who want to know which parts of the lungs are functioning, which have obstruction, and how effective new therapies are,” noted Jason C. Woods, Ph.D., the director of pulmonary research at the Cincinnati Children’s Hospital and the University of Cincinnati. “The partnership between Philips and Polarean demonstrates a cutting-edge technique can be rapidly incorporated into a major MRI platform without sacrificing quality.”
